1. Signaling Pathways
  2. Antibody-drug Conjugate/ADC Related
  3. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-100566
    SuO-Val-Cit-PAB-MMAE
    99.24%
    SuO-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB.
    SuO-Val-Cit-PAB-MMAE
  • HY-130990
    DBCO-PEG4-Val-Cit-PAB-MMAF
    99.99%
    DBCO-PEG4-Val-Cit-PAB-MMAF consists a cleavable 4 unit PEG ADC linker (DBCO-PEG4-Val-Cit-PAB) and a potent tubulin polymerization inhibitor (MMAF). DBCO-PEG4-Val-Cit-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs). DBCO-PEG4-Val-Cit-PAB-MMAF is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-PEG4-Val-Cit-PAB-MMAF
  • HY-100567
    MAL-di-EG-Val-Cit-PAB-MMAE
    98.04%
    MAL-di-EG-Val-Cit-PAB-MMAE consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin inhibitor (MMAE).
    MAL-di-EG-Val-Cit-PAB-MMAE
  • HY-139642
    Mal-(CH2)5-Val-Cit-PAB-Eribulin
    99.82%
    Mal-(CH2)5-Val-Cit-PAB-Eribulin is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB.
    Mal-(CH2)5-Val-Cit-PAB-Eribulin
  • HY-128968
    PEG4-aminooxy-MMAF
    99.83%
    PEG4-aminooxy-MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the potent antitubulin agent MMAF, linked via the noncleavable PEG4.
    PEG4-aminooxy-MMAF
  • HY-135660
    MMAE-SMCC
    99.56%
    MMAE-SMCC is a agent-linker conjugate for ADC. MMAE-SMCC is composed of a potent mitotic and a tubulin inhibitor MMAE and a linker SMCC to make antibody agent conjugate.
    MMAE-SMCC
  • HY-136170
    MC-SN38
    98.65%
    MC-SN38 is a agent-linker conjugate composed of a potent microtubule-disrupting agent SN38 and a non-cleavable MC linker to make antibody agent conjugate (ADC). SN-38, an active metabolite of the Topoisomerase I inhibitor Irinotecan, inhibits DNA synthesis and causes frequent DNA single-strand breaks.
    MC-SN38
  • HY-111012
    DBCO-(PEG)3-VC-PAB-MMAE
    Chemical
    DBCO-(PEG)3-VC-PAB-MMAE is a agent-linker conjugate for ADC. DBCO-(PEG)3-VC-PAB-MMAE is made by auristatin E.html" class="link-product" target="_blank">Monomethyl auristatin E (HY-15162) conjugats to DBCO-(PEG)3-vc-PAB linker. DBCO-(PEG)3-VC-PAB-MMAE can be used for the research of cancer. DBCO-(PEG)3-VC-PAB-MMAE is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-(PEG)3-VC-PAB-MMAE
  • HY-126690
    DBCO-(PEG2-VC-PAB-MMAE)2
    98.73%
    DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)2 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody agent conjugate. DBCO-(PEG2-VC-PAB-MMAE)2 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-(PEG2-VC-PAB-MMAE)2
  • HY-141155
    endo-BCN-PEG4-Val-Cit-PAB-MMAE
    98.84%
    endo-BCN-PEG4-Val-Cit-PAB-MMAE is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). endo-BCN-PEG4-Val-Cit-PAB-MMAE is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    endo-BCN-PEG4-Val-Cit-PAB-MMAE
  • HY-153180
    PB038
    PB038 is a Drug-liker containing a PEG unit and a cleavable linker attached to Exatecan.
    PB038
  • HY-100874
    N3-PEG3-vc-PAB-MMAE
    98.56%
    N3-PEG3-vc-PAB-MMAE is a synthesized agent-linker conjugate for ADC that incorporates the MMAE (a tubulin inhibitor ) and 3-unit PEG linker. N3-PEG3-vc-PAB-MMAE shows potent antitumor activity. N3-PEG3-vc-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
    N3-PEG3-vc-PAB-MMAE
  • HY-101982
    Lys-SMCC-DM1
    99.61%
    Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is a agent-linker conjugates for ADC that can inhibit tubulin polymerization. Lys-SMCC-DM1 is the active metabolite of T-DM1. T-DM1 is a HER2-targeting ADC with a tubulin polymerization inhibitor DM1. Lys-SMCC-DM1 can be used in the research of breast cancer.
    Lys-SMCC-DM1
  • HY-130812
    Gemcitabine-O-Si(di-iso)-O-Mc
    98.79%
    Gemcitabine-O-Si(di-iso)-O-Mc is a agent-linker conjugate for ADC with potent antitumor activity by using Gemcitabine (a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent; HY-17026), linked via the ADC linker.
    Gemcitabine-O-Si(di-iso)-O-Mc
  • HY-128943
    MAC glucuronide phenol-linked SN-38
    98.49%
    MAC glucuronide phenol-linked SN-38 is a pH-susceptible lactone MAC glucuronide phenol-linked SN-38 (DNA topoisomerase I inhibitor) agent linker. MAC glucuronide phenol-linked SN-38 is cytotoxic across L540cy cells and Ramos cells with IC50 values of 113 and 67 ng/mL, respectively.Albumin-coupled MAC glucosidol-linked SN-38 shows good stability in mouse plasma.
    MAC glucuronide phenol-linked SN-38
  • HY-148426
    OSu-PEG4-VC-PAB-MMAE
    OSu-PEG4-VC-PAB-MMAE involves in GDP-FAmP4MMAE (Monomethylauristatin E) synthesis, which is for GDP label via site-specific conjugation.
    OSu-PEG4-VC-PAB-MMAE
  • HY-16261B
    MC-DOXHZN hydrochloride
    ≥98.0%
    MC-DOXHZN ((E/Z)-Aldoxorubicin) hydrochloride is an albumin-binding proagent of Doxorubicin (DNA topoisomerase II inhibitor), with acid-sensitive properties.
    MC-DOXHZN hydrochloride
  • HY-104025
    SPB
    98.20%
    SPB is a agent-linker conjugate for ADC with potent anti-inflammatory activity by using Xanthotoxol, linked via the ADC linker.
    SPB
  • HY-101152
    SG3199-Val-Ala-PAB
    SG3199-Val-Ala-PAB is an intermediate of Tesirine synthesis. Tesirine is a agent-linker conjugate for ADC which can be used for the research of several cancers.
    SG3199-Val-Ala-PAB
  • HY-130989
    SuO-Glu-Val-Cit-PAB-MMAE
    99.20%
    SuO-Glu-Val-Cit-PAB-MMAE (NHS-Glutarate-Val-Cit-PAB-MMAE) consists a cleavable ADC linker (SuO-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs).
    SuO-Glu-Val-Cit-PAB-MMAE

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.